Article Text

PDF
A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab
  1. Manoj Ray1,
  2. Jeffrey R Curtis2,
  3. John W Baddley1
  1. 1 Department of Medicine/Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Birmingham, Alabama, USA
  2. 2 Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA
  1. Correspondence to Dr John W Baddley, Department of Medicine/Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, 229 THT, Birmingham, AL 35294-0006, USA; jbaddley{at}uab.edu

Statistics from Altmetric.com

Case report

Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by polyomavirus JC. It results from lytic infection of glial cells and is often fatal.1 ,2 A common risk factor for PML is immunosuppression due to HIV infection or malignancy (or its treatment). PML has also been reported in those using immunomodulation therapies.3 A previous study estimated incidence of PML at 0.2/100 000 among patients with autoimmune diseases who did not have HIV or malignancy. Based on the single case of PML exposed to a biological agent, another study reported the incidence rate (IR) of PML was 2.3 (95% CI 0.1 to 71) per 100 000 person-years in patients who were exposed to biological agents and 0.8 (95% CI 0.2 to 2.5) per 100 000 person-years in those not exposed to biological agents.4

Cases of PML associated …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.